Based on reports of elevated serum levels in patients with non-cutaneous neuroendocrine tumors [7–12], some institutions follow neuron specific enolase (NSE) and chromogranin A (ChrA) blood levels in MCC patients. This evidence concerns the gene ENO2 and neuroendocrine neoplasm.